secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001213900-25-050329
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma raises ~$3.35M in PIPE at $1.50/share
-----------------------------------------------------------

- Issued 2,233,334 shares at $1.50 each (premium to $1.00 close on May 29, 2025).
- Net proceeds to fund Phase I STARLIGHT-1 trial of EB103 CD19-targeted T-cell therapy in NHL.
- True-Up provision: additional shares if 12-month closing price below $1.50 (floor $0.20).
- Company agreed to file resale registration statement for shares issued in PIPE.
- Closing subject to customary conditions; investor support cited as confidence in ARTEMIS platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390025050329/0001213900-25-050329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390025050329/ea0244428-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-050329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer